Title: Prospective application of bioinformatics in the treatment of Alzheimer’s disease

Biography:

Dr. Namrata Agarwal has completed her MBBS at the age of 27 years from Kathmandu University, Nepal. She is director of Pharmacy in Dr. M.C Saxena group of colleges. 

Abstract

Alzheimer's disease is a progressive neurodegenerative neurologic disease that results in the irreversible loss of neurons, particularly in the cortex and hippocampus. The disease is characterized by low levels in the brain of the neurotransmitters acetylcholine (ACh) and dopamine (DA), respectively. The acetylcholine is mainly inhibited by the acetylcholinesterase which is a hydrolase that hydrolyzes choline esters. Major advances in the treatment of AD have been the use of acetylcholinesterase inhibitors such as Sulmepride, Promazine hydrochloride to increase the levels of ACh rather than the use of cholinergic compounds. In this first approach, it was found that approved drug against the acetylcholinesterase was 1516, in the approved drug library and out of these 17 were found to have a similar structure (using Swiss similarity ) like promazine hydrochloride. Then we applied ADMET and as a result, we got 10 compounds which fulfilled the ADMET criteria, then these 10 compounds were subjected to Lipinski rule of five (RO5) and out of these best two compounds were found having the ID DB00548, DB00770  ( azelaic acid & alprostadil respectively). Further molecular docking of these two compounds will be carried out using autodock4.0